TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$257.025 Million

Kymera Therapeutics, Inc.

Follow-on Offering

Bookrunner, June 2021

Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. (the “Company” or “Kymera”) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s Pegasus platform enables the discovery of highly selective small molecule protein degraders with activity against disease causing proteins throughout the body. Kymera’s initial programs are IRAK4, IRAKIMiD, and STAT3, each of which addresses high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.